<DOC>
	<DOCNO>NCT01972282</DOCNO>
	<brief_summary>The WATCHMAN LAA Closure Technology design prevent embolization thrombus may form LAA , thereby prevent occurrence ischemic stroke systemic thromboembolism . The objective observational , prospective , non-randomized multicenter study ( 1 ) compile real-world clinical outcome data WATCHMAN LAA ( leave atrial appendage ) Close Technology patient implant WATCHMAN device commercial clinical setting ( 2 ) collect real-world usage data may need reimbursement WATCHMAN technology certain country .</brief_summary>
	<brief_title>Registry WATCHMAN Outcomes Real-Life Utilization</brief_title>
	<detailed_description>Approximately 1000 subject enrol study . To reduce impact individual center bias , site may include 45 subject country may include maximum 500 patient . Up 70 site ( international , outside US ) participate study . Primary analysis may include , limited , follow : procedural complication , incidence stroke death . Descriptive statistic use baseline , procedure follow-up data collect study . Each patient follow period two year enrollment accord schedule standard practice enrol center . There additional visit , procedure , subject participate study . Subjects expect followed implant , one post-implant visit ( typically 1-3 month implant ) , annually 2 year post implant . An intermediate visit may schedule number patient , per physician discretion . In order reliably capture patient status study end , follow-up window 24 +/- 3 month consider acceptable schedule last visit . For subject schedule visit clinic follow-up , subject contact ( e.g . phone call ) ensure capture endpoint relate information ; however , recommend perform in-office visit least first annual visit . Enrollment expect complete 21 month ; therefore , total study duration estimate 48 month .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<criteria>Patients eligible WATCHMAN device accord current international local guideline ( future revision ) per physician discretion ; Patient willing capable providing informed consent , participate test associate clinical investigation approve clinical investigational center ; Patients whose age 18 year , legal age give inform consent specific state national law . Patient currently enrol another investigational study registry would directly interfere current study , except patient participate mandatory governmental registry , purely observational registry associate treatment . Each instance bring attention sponsor determine eligibility ; Women childbearing potential , plan become , pregnant time study ( method assessment upon physician 's discretion ) ; The subject unable willing complete followup visit examination duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Thrombus</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Left atrial appendage</keyword>
</DOC>